MX2021012964A - Polipeptido de fusion que comprende region fc de inmunoglobulina y gdf15. - Google Patents

Polipeptido de fusion que comprende region fc de inmunoglobulina y gdf15.

Info

Publication number
MX2021012964A
MX2021012964A MX2021012964A MX2021012964A MX2021012964A MX 2021012964 A MX2021012964 A MX 2021012964A MX 2021012964 A MX2021012964 A MX 2021012964A MX 2021012964 A MX2021012964 A MX 2021012964A MX 2021012964 A MX2021012964 A MX 2021012964A
Authority
MX
Mexico
Prior art keywords
gdf15
immunoglobulin
region
fusion polypeptide
fusing
Prior art date
Application number
MX2021012964A
Other languages
English (en)
Inventor
Saem Jung
Yeonchul Kim
Kyeongsik Min
Young Dok Son
Kyubong Na
Ji Ho Hong
Myung Won Jin
Park Ji A
Soomin Noh
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2021012964A publication Critical patent/MX2021012964A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporciona un polipéptido de fusión que comprende GDF15 (factor de diferenciación de crecimiento 15) y una región Fc de inmunoglobulina, una composición farmacéutica que comprende el polipéptido de fusión y un método de aumentar la duración in vivo de GDF15 que comprende fusionar con una región Fc de inmunoglobulina.
MX2021012964A 2019-04-23 2020-04-22 Polipeptido de fusion que comprende region fc de inmunoglobulina y gdf15. MX2021012964A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190047558 2019-04-23
PCT/KR2020/005324 WO2020218827A1 (ko) 2019-04-23 2020-04-22 면역글로불린의 Fc 영역 및 GDF15를 포함하는 융합 폴리펩타이드

Publications (1)

Publication Number Publication Date
MX2021012964A true MX2021012964A (es) 2021-12-10

Family

ID=72941168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012964A MX2021012964A (es) 2019-04-23 2020-04-22 Polipeptido de fusion que comprende region fc de inmunoglobulina y gdf15.

Country Status (19)

Country Link
US (1) US20230053119A1 (es)
EP (1) EP3978518A4 (es)
JP (2) JP2022530216A (es)
KR (2) KR20200124176A (es)
CN (1) CN113767112A (es)
AU (1) AU2020260931B2 (es)
BR (1) BR112021021271A2 (es)
CA (1) CA3136969A1 (es)
CL (1) CL2021002757A1 (es)
CO (1) CO2021014413A2 (es)
IL (1) IL287343A (es)
JO (1) JOP20210282A1 (es)
MX (1) MX2021012964A (es)
PE (1) PE20220500A1 (es)
SG (1) SG11202111570TA (es)
TW (2) TW202100563A (es)
UA (1) UA128626C2 (es)
WO (1) WO2020218827A1 (es)
ZA (1) ZA202108437B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4351628A1 (en) * 2021-05-21 2024-04-17 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
CN115925982A (zh) * 2021-08-24 2023-04-07 广东东阳光药业有限公司 Gdf15融合蛋白及其用途
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ282849A (en) * 1994-03-29 1998-05-27 Celltech Therapeutics Ltd Antibodies against e-selectin; whole antibodies of neutral isotype, being variants of natural antibodies altered in the fc region
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7736653B2 (en) * 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
KR101038126B1 (ko) 2010-11-30 2011-05-31 주식회사 엘지생명과학 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터
KR101868139B1 (ko) 2010-11-30 2018-06-15 주식회사 엘지화학 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터
ES2942455T3 (es) * 2011-04-13 2023-06-01 Bristol Myers Squibb Co Proteínas de fusión Fc que comprenden enlazadores o disposiciones nuevos
BR112014018575A2 (pt) * 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
US9550819B2 (en) * 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP2950807B1 (en) * 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
LT3027642T (lt) * 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
KR102092225B1 (ko) 2014-04-30 2020-03-23 주식회사 엘지화학 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
MD20170035A2 (ro) * 2014-10-31 2017-09-30 Ngm Biopharmaceuticals Inc Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
SI3298030T1 (sl) * 2015-05-18 2023-05-31 Pieris Pharmaceuticals Gmbh Protirakav fuzijski polipeptid
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
EP3393494A1 (en) * 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2019199685A1 (en) * 2018-04-09 2019-10-17 Amgen Inc. Growth differentiation factor 15 fusion proteins

Also Published As

Publication number Publication date
BR112021021271A2 (pt) 2021-12-21
SG11202111570TA (en) 2021-11-29
EP3978518A4 (en) 2022-11-02
CO2021014413A2 (es) 2021-11-19
IL287343A (en) 2021-12-01
CA3136969A1 (en) 2020-10-29
CL2021002757A1 (es) 2022-06-10
JP2022530216A (ja) 2022-06-28
TW202337914A (zh) 2023-10-01
WO2020218827A1 (ko) 2020-10-29
US20230053119A1 (en) 2023-02-16
KR20210080339A (ko) 2021-06-30
ZA202108437B (en) 2023-07-26
TW202100563A (zh) 2021-01-01
CN113767112A (zh) 2021-12-07
AU2020260931B2 (en) 2023-08-24
PE20220500A1 (es) 2022-04-07
AU2020260931A1 (en) 2021-12-09
KR20200124176A (ko) 2020-11-02
UA128626C2 (uk) 2024-09-04
JP2023115118A (ja) 2023-08-18
EP3978518A1 (en) 2022-04-06
JOP20210282A1 (ar) 2023-01-30
KR102609627B1 (ko) 2023-12-04

Similar Documents

Publication Publication Date Title
MX2021012964A (es) Polipeptido de fusion que comprende region fc de inmunoglobulina y gdf15.
EP4364724A3 (en) High concentration vegf receptor fusion protein containing formulations
AU2018351050A8 (en) Compositions and methods for selective protein degradation
WO2020231882A3 (en) Modified pluripotent cells
WO2016065326A3 (en) Modified fgf-21 polypeptides and uses thereof
EA202092316A1 (ru) Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
MX2023001595A (es) Proteinas de fusion que comprenden proteinas de leche y composiciones de las mismas.
WO2020082042A3 (en) Compositions and methods for transgene expression from an albumin locus
MX2021004665A (es) Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas.
CR20200510A (es) Protreínas de fusión del factor de diferenciación de crecimiento 15
MX2022009302A (es) Compuestos de unión a il-7r¿.
EP3999079A4 (en) FUSION POLYPEPTIDE FOR IMMUNOTHERAPY
MX2022002747A (es) Proteinas de fusion de ca2-il15 para regulacion ajustable.
EP3735458A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
MX2020006635A (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
MX2021010061A (es) Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1.
AP1968A (en) Recombinant rhabdovirus containing a heterologous fusion protein.
EP3994275A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
WO2019108924A3 (en) Cdkl5 expression variants and cdkl5 fusion proteins
EP4063385A4 (en) GIPR ANTIBODY AND FUSION PROTEIN BETWEEN THE SAME AND GLP-1, AND PHARMACEUTICAL COMPOSITION AND ASSOCIATED APPLICATION
EP3978033A4 (en) RK POLYPEPTIDE RADIOPHARMACEUTICAL FOR TARGETING HER2 AND METHODS OF PRODUCTION
ZA202206992B (en) Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
MX2022009101A (es) Proteinas heterodimericas con mutaciones fc.
CR20220107A (es) Proteínas de fusión nkg2d y sus usos
PH12019501765A1 (en) Factor ix fusion proteins and methods of making and using same